In the context of cancer, dipyridamole has been shown to inhibit statin‐induced SREBP2 cleavage and activation in AML, MM, breast cancer, and prostate cancer cells [3, 4, 6], suggesting similar regulation in many different cell types. This evidence concerns the gene SREBF2 and Miyoshi myopathy.